Pathstone Family Office’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-133
Closed -$11K 1364
2020
Q3
$11K Buy
+133
New +$15.5K ﹤0.01% 591

Other funds holding VBIV

Pathstone Family Office's VBIV Position: Q4 2020 in Review

Pathstone Family Office sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q4 2020, closing a stake of 133 shares — an estimated $11K sold.

Pathstone Family Office first reported a position in VBIV in Q3 2020 and held it in 1 quarter. The position peaked at $11K in Q3 2020. 122 funds tracked by Wall St. Rank hold VBIV as of Q4 2020.

  • Pathstone Family Office reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q4 2020 after selling out during the quarter.
  • Pathstone Family Office sold 133 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q4 2020, an estimated $11K.
  • Pathstone Family Office first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2020 and held it in 1 quarter.
  • Pathstone Family Office's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $11K in Q3 2020.
  • 122 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q4 2020.

Based on Pathstone Family Office's 13F filing for Q4 2020, filed 16 Feb 2021.